Navigation Links
NicOx Reports Results for the First Three Quarters of 2008
Date:10/22/2008

zer's decision not to launch a

phase 3 program.

Eric Castaldi, Chief Financial Officer at NicOx, said: "During the third quarter of 2008 we have achieved considerable success in the development of naproxcinod, while keeping the necessary control on expenses. We are very encouraged by the positive top-line results from the 302 phase 3 study, which comfortably met its efficacy endpoints and supported naproxcinod's non-detrimental effect on blood pressure, as well as by the good long term safety data observed in the 301 extension study.

We have also significantly advanced our pre-launch activities for naproxcinod, through the signature of an agreement for the manufacture of naproxcinod capsules for future commercialization, and are confident that the New Drug Application will be filed in mid 2009 as planned. We remain focused on the finalization of the clinical program for naproxcinod and look forward to the results of the 303 phase 3 study and the 111 and 112 Ambulatory Blood Pressure Monitoring studies in the coming months. As anticipated, our cash balance at the end of the third quarter is EUR124.8 million, which will enable us to fully finance the remaining clinical trials for naproxcinod and continue to advance the development of the other compounds in our portfolio."

Financial summary of the first nine months of 2008:

Revenues were EUR2.9 million for the nine months ended September 30, 2008, compared to EUR18.4 million during the same period in 2007. These revenues were due to the allocation of payments received from Pfizer Inc and Merck & Co., Inc. following the agreements signed with the two companies in the fields of ophthalmology and hypertension, respectively.

For the first nine months of 2008, operating expenses were EUR60.4 million, compared to EUR39.0 million for the corresponding period of 2007. As expected, the majority of these expenses were due to research and development costs related to naproxcinod, NicOx'
'/>"/>

SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. NicOx Signs Agreement With Capsugel for the Commercial Manufacture of Naproxcinod Oral Capsules
2. NicOx Announces Departure of Damian Marron for CEO Position
3. NicOx Signs Agreement for the Commercial Manufacture of Naproxcinod Drug Substance
4. NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis
5. NicOx to Present at Financial Conferences in New York on November 27, 28 and 29
6. NicOx Opens U.S. Headquarters in New Jersey
7. Wyeth Reports Earnings Results for the 2008 Third Quarter and First Nine Months
8. Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares.
9. Amylin Pharmaceuticals Reports Third Quarter Financial Results
10. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
11. Glycotex Reports First Patient Enrollment in Phase IIb Study of Lead Product Candidate GLYC-101 for Wound Healing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... About Bioactive Material Bioactive ... are increasingly becoming popular due to their ability ... having a negative impact on the human health. ... tissue repair materials in surgical procedures. Bioactive materials ... glass-ceramics, and composites. The major end-users of bioactive ...
(Date:9/23/2014)... 23, 2014 Kamal Rashid , ... Education and Training Center (BETC) and research professor of ... BioTalk 2014 , an international two-day event focused on ... by Global Summits, the event will bring together leaders ... cells to develop and produce human therapeutics. “The growth ...
(Date:9/23/2014)... 2014 This is a professional ... the Phenolic Resin industry in Global and China.The ... including definitions, applications and industry chain structure. Global ... provided with a focus on history, developments, trends ... between the international and Chinese situation is also ...
(Date:9/23/2014)... Erlab , the expert in ... and Burdinola, supplier of laboratory furniture solutions, announce a ... hood. , By integrating Erlab’s GreenFumeHood ... now offer an innovative solution utilizing the patented technology ... best-in-class detection technology, and communication for security and monitoring ...
Breaking Biology Technology:Global Bioactive Material Market 2014-2018 2Worcester Polytechnic Institute's Biomanufacturing Expertise to be Featured in Berlin 2Worcester Polytechnic Institute's Biomanufacturing Expertise to be Featured in Berlin 3Phenolic Resin Industry (International, China) Development Policy and Plan Now Available at ReportsnReports.com 2Erlab Partners with Burdinola to Deliver an Innovative Filtered Fume Hood 2
... India, September 9 , ... Consulting Solutions for Health Care , ... the launch of its first business vertical-focused learning,solutions for ... initiative with the appointment of Candida Chandorkar as Vice,President ...
... WILMINGTON, N.C., Sept. 9 Jim Robison has been named ... several new Sanford Rose Associates executive search offices opening in ... Environmental Systems and CFO of House of Raeford Farms. With ... growing agribusiness, food processing, and distribution companies, Robison is a ...
... ... designed to find the genetic cause of Chiari-like Malformation and syringomyelia in dogs. Chiari-like malformation ... out of the skull and crowds the spinal cord, putting pressure on both the brain ... ...
Cached Biology Technology:Tata Interactive Systems Initiates Vertical-Focused Learning Solutions for Health Care, Pharmaceutical, and Biotechnology 2Tata Interactive Systems Initiates Vertical-Focused Learning Solutions for Health Care, Pharmaceutical, and Biotechnology 3Tata Interactive Systems Initiates Vertical-Focused Learning Solutions for Health Care, Pharmaceutical, and Biotechnology 4Sanford Rose Associates Opens Wilmington, N.C. Office 2DNA Genotek's Oragene●ANIMAL DNA Collection Kit Plays Key Role in Determining the Genetic Cause of Chiari Malformation in Dogs 2DNA Genotek's Oragene●ANIMAL DNA Collection Kit Plays Key Role in Determining the Genetic Cause of Chiari Malformation in Dogs 3
(Date:9/23/2014)... 23, 2014 Research and Markets  has ... Forecast and Opportunities, 2019" report to their offering. ... for enhancing security and protection in private as well ... The country,s government is focusing on using biometric systems ... other national IDs that are of crucial importance to ...
(Date:9/23/2014)... Florida , September 23, 2014 ... innovative companies in tech sector position for significant investor attention ... & services.  Companies in focus today are: NXT-ID, Inc. (NASDAQ: ... BABA ), Mobileye N.V. (NYSE: MBLY ), ... Ltd. (NASDAQ: RWLK) NXT-ID, Inc. (NASDAQ: ...
(Date:9/23/2014)... including humans, have parasitic DNA fragments called "jumping genes" ... in the process. And that phenomenon can result in ... University of Rochester now report that the "jumping genes" ... a multi-function protein stops keeping them in check in ... a study published today in Nature Communications , ...
Breaking Biology News(10 mins):India Biometrics Market Forecast and Opportunities, 2019 2India Biometrics Market Forecast and Opportunities, 2019 3Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 2Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 3Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 4Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 5Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 6Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 7A multi-function protein is key to stopping genomic parasites from 'jumping' 2
... study from the University of Rochester finds that there is ... it language capabilities above and beyond those of any other ... brain, each designed to accomplish different primitive tasks, in order ... of grammar used in forming a given sentence, the brain ...
... have developed a way to enhance how brain tumors appear ... for surgeons to identify and remove. Scientists at Ohio ... may one day be injected into the blood of patients ... In the journal Nanotechnology, researchers reported that ...
... An international research consortium including scientists from The ... (UTHealth) has identified a new genetic link to ... thorough understanding of the genetic nature of the ... Systemic scleroderma is a profoundly disabling autoimmune disease ...
Cached Biology News:Sign language study shows multiple brain regions wired for language 2Sign language study shows multiple brain regions wired for language 3Tiny particles may help surgeons by marking brain tumors 2Study reveals new genetic link to scleroderma 2Study reveals new genetic link to scleroderma 3
... BR4i refrigerated multifunction centrifuges are equally capable of ... low sound level with a large range of ... rotor exchange system without tools ensures that the ... Instant rotor exchange (5 sec.) ...
... ,Each upright model provides fast pull-down, rapid ... for refrigerated blood. The BBR25 and BBR55 ... complete blood storage monitoring. Models BBR6, BBR11, ... HemaPro 101 alarm/monitor. All of these models ...
Sterile, individually wrapped, 4mm Cuvettes...
... form of Tobacco Etch Virus (TEV) protease ... significantly more stable than native TEV protease, ... recognizes a seven amino acid (Glu-Asn-Leu-Tyr-Phe-Gln-Gly, cleaving ... for removing affinity tags from fusion proteins ...
Biology Products: